KEAP1 and obesity disorder: The KEAP1-NRF2/ARE pathway has garnered significant interest not only in kidney diseases but also in various other fields, including cancer, Alzheimer’s disease (AD), Parkinson’s disease, chronic obstructive pulmonary disease (COPD), asthma, atherosclerosis, diabetes, multiple sclerosis (MS), osteoarthritis, rheumatoid arthritis, and obesity [191].